Close Menu
NEW YORK (GenomeWeb News) – ChondroGene today said that second-quarter revenue slid 42 percent as R&D spending rose by nearly one-third and net losses swelled 160 percent.
 
Total receipts for the three months ended June 30 declined to CA$873,020 ($781,020) from CA$1.5 million year over year. ChondroGene said the current quarter’s results comprise a CA$679,228 amortized one-time payment from Pfizer as part of an R&D alliance penned in 2004 and around CA$194,000 in fee and service revenue.
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.

Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.

Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.

In Science this week: three studies from the Ruminant Genome Project, and more.